Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 4/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.61 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.61 |
| ▸ | DRD2 | P14416 | 2/20 | 0.59 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | PDE5A | O76074 | 4/20 | 0.51 |
| ▸ | PRMT5 | O14744 | 4/20 | 0.50 |
| ▸ | EGFR | P00533 | 3/20 | 0.49 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14599797 | 1.00 | HTR7 (0.61) | HTR7CYP3A4CYP2D6CYP2C19DRD2 | |
| SCHEMBL2504528 | 1.00 | HTR7 (0.61) | HTR7CYP3A4CYP2D6CYP2C19DRD2 | |
| SCHEMBL5532312 | 1.00 | HTR7 (0.61) | HTR7CYP3A4CYP2D6CYP2C19DRD2 | |
| SCHEMBL7491493 | 0.88 | HTR7 (0.64) | HTR7CYP3A4CYP2D6CYP2C19DRD2 | |
| SCHEMBL7492089 | 0.83 | HTR7 (0.65) | HTR7CYP3A4CYP2D6CYP2C19DRD2 | |
| SCHEMBL5740140 | 0.83 | HTR7 (0.65) | HTR7CYP3A4CYP2D6CYP2C19DRD2 | |
| SCHEMBL5790730 | 0.83 | HTR7 (0.65) | HTR7CYP3A4CYP2D6CYP2C19DRD2 | |
| SCHEMBL2502972 | 0.83 | PDE5A (0.60) | PDE5A | |
| SCHEMBL2509857 | 0.83 | PDE5A (0.60) | PDE5A | |
| Hydrochloric Acid SCHEMBL5537994 | 0.82 | PDE5A (0.59) | PDE5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110245503-A1 | ENANTIOSELECTIVE SYNTHESIS OF ASYMMETRIC BETA-CARBOLINE INTERMEDIATES | UNIVERSIDAD DE TALCA (CL) | 2011-10-06 | — | — | US | disclosed |
| US-20110245503-A1 | ENANTIOSELECTIVE SYNTHESIS OF ASYMMETRIC BETA-CARBOLINE INTERMEDIATES | UNIVERSIDAD DE TALCA (CL) | 2011-10-06 | — | — | US | disclosed |
| WO-2010060228-A1 | ENANTIOSELECTIVE SYNTHESIS OF ASYMMETRIC BETA-CARBOLINE INTERMEDIATES | UNIVERSIDAD DE TALCA (CL) | 2010-06-03 | — | — | WO | disclosed |
| US-20080103164-A1 | USEFUL COMPOUNDS FOR HPV INFECTION | SMITHKLINE BEECHAM CORPORATION | 2008-05-01 | — | — | US | disclosed |
| US-20080103164-A1 | USEFUL COMPOUNDS FOR HPV INFECTION | SMITHKLINE BEECHAM CORPORATION | 2008-05-01 | — | — | US | disclosed |
| US-20070015798-A1 | Efficient and stereoselective process for large scale synthesis of (3R)-3-(2,3-dihydrobenzofuran-5-yl)-1,2,3,4-tetrahydropyrrolo[3,4-b]quinolin-9-one derivatives | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-01-18 | — | — | US | disclosed |
| US-20070015798-A1 | Efficient and stereoselective process for large scale synthesis of (3R)-3-(2,3-dihydrobenzofuran-5-yl)-1,2,3,4-tetrahydropyrrolo[3,4-b]quinolin-9-one derivatives | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-01-18 | — | — | US | disclosed |
| US-20070015798-A1 | Efficient and stereoselective process for large scale synthesis of (3R)-3-(2,3-dihydrobenzofuran-5-yl)-1,2,3,4-tetrahydropyrrolo[3,4-b]quinolin-9-one derivatives | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-01-18 | — | — | US | disclosed |
| US-7022856-B2 | Carboline derivatives | LILLY ICOS LLC. (US) | 2006-04-04 | — | — | US | disclosed |
| EP-1360185-B1 | CARBOLINE DERIVATIVES | LILLY ICOS LLC (US) | 2005-08-24 | — | — | EP | disclosed |
| US-6635638-B2 | Treatment of sexual dysfunction, cardiovascular system disorders | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2003-10-21 | — | — | US | disclosed |
| US-6462047-B1 | CONTAINING 5- OR 6-MEMBERED OXYGEN, NITROGEN AND/OR SULFUR HETEROARYL GROUP; ANGINA, HYPERTENSION, RESPIRATORY DISTRESS, CONGESTIVE HEART FAILURE, RENAL FAILURE, ATHEROSCLEROSIS, INFLAMMATORY DISEASES, STROKES, BRONCHITIS, ASTHMA | ICOS CORPORATION | 2002-10-08 | — | — | US | disclosed |
| US-20020072055-A1 | Iterative and regenerative DNA sequencing method | THE UNIVERSITY OF IOWA RESEARCH FOUNDATION | 2002-06-13 | — | — | US | disclosed |
| EP-0912567-B1 | CARBOLINE DERIVATIVES | ICOS CORP (US) | 2002-04-10 | — | — | EP | disclosed |
| US-20020010183-A1 | Substituted pyrrolopyridinone derivatives useful as phosphodiesterase inhibitors | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2002-01-24 | — | — | US | disclosed |
| US-6306870-B1 | PHOSPHODIESTERASE ENZYME INHIBITORS, CARDIOVASCULAR DISORDERS AND SEXUAL DISORDERS | ICOS CORPORATION | 2001-10-23 | — | — | US | disclosed |
| US-6117881-A | POTENT AND SELECTIVE INHIBITORS OF CYCLIC GUANOSINE 3',5'-MONOPHOSPHATE SPECIFIC PHOSPHODIESTERASE | ICOS CORPORATION (US) | 2000-09-12 | — | — | US | disclosed |
| US-6043252-A | A POTENT AND SELECTIVE INHIBITORS OF CYCLIC GUANOSINE 3',5'-MONOPHOSPHATE SPECIFIC PHOSPHODIESTERASE (CGMP-SPECIFIC PDE); TREATING CARDIOVASCULAR DISORDERS AND ERECTILE DYSFUNCTION | ICOS CORPORATION (US) | 2000-03-28 | — | — | US | disclosed |
| EP-0912567-A1 | CARBOLINE DERIVATIVES | ICOS CORPORATION (US) | 1999-05-06 | — | — | EP | disclosed |
| WO-1997043287-A1 | CARBOLINE DERIVATIVES | ICOS CORPORATION (US) | 1997-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110245503-A1 | ENANTIOSELECTIVE SYNTHESIS OF ASYMMETRIC BETA-CARBOLINE INTERMEDIATES | PDE1B, PDE3B, PDE1A | HTR7 443/4885CYP3A4 177/4885CYP2D6 439/4885 |
| US-20020010183-A1 | Substituted pyrrolopyridinone derivatives useful as phosphodiesterase inhibitors | PDE5A, PDE3A, PDE3B | HTR7 1742/4885CYP3A4 683/4885CYP2D6 456/4885 |
| US-20080103164-A1 | USEFUL COMPOUNDS FOR HPV INFECTION | TP53, POLI, PCNA | HTR7 3742/4885CYP3A4 4050/4885CYP2D6 4192/4885 |
| US-20070015798-A1 | Efficient and stereoselective process for large scale synthesis of (3R)-3-(2,3-dihydrobenzofuran-5-yl)-1,2,3,4-tetrahydropyrrolo[3,4-b]quinolin-9-one derivatives | PDE5A, PDE3A, PDE3B | HTR7 777/4885CYP3A4 155/4885CYP2D6 184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.